Mateon Therapeutics Appoints Dr. Anthony Maida as Chief Clinical Officer - Translational Medicine Company expands its management team to accelerate the evaluation of OT-101 for Oncology and COVID-19 Agoura Hills, California, July 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB:...

MATEON IS SELECTED BY IBM WATSON HEALTH FOR THE USE OF IBM CLINICAL DEVELOPMENT SOLUTION AT NO COST FOR PHASE II CLINICAL TRIAL OF OT-101 FOR COVID-19 Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates AGOURA HILLS,...

Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...

MATEON AND GMP COMPLETED RESEARCH AND SERVICE AGREEMENT -  Mateon and GMP to proceed to clinical development of OT-101 and Artemisin and other antisense drug candidates against COVID-19 AGOURA HILLS, Calif., June 22, 2020 (GLOBE NEWSWIRE) --...